Novartis AG is enlisting the help of Generate:Biomedicines Inc. and its artificial intelligence platform to generate drugs for multiple undisclosed targets. The number of targets and therapeutic areas also weren’t disclosed. Novartis will pick the targets, although the targets Generate has been working on are off limits. Generate will be responsible for creating the lead candidate, at which point Novartis will take over development.
Scientists and doctors are getting much better at developing treatments for cancer. More than 18 million people with a history of cancer were alive in the U.S. at the beginning of 2022, up from just 3 million in 1971, according to the 14th edition of the American Association for Cancer Research (AACR) Cancer Progress Report. And that number is expected to rise to 26 million by 2040.
Biocom California’s most recent edition of its Let's Talk About series covered the future of women’s health. The panel of executives from companies and investors in women’s health were frustrated about the state of funding for the space. “Only about 1% of health care R&D dollars go [specifically] to women’s health outside of oncology,” Jenn Kiang, director of corporate affairs and development at Daré Bioscience Inc. told the audience. But the opportunity is huge, she said.
Vironexis Biotherapeutics Inc. has come out of stealth mode, disclosing that it has more than 10 product candidates it’s been developing over the last three years. The therapies are built on the company’s AAV-based platform, Transjoin, which is designed to have patients' livers express bispecific antibodies that bind to both CD3 on T-cells and various targets on tumor cells.
Vironexis Biotherapeutics Inc. came out of stealth mode today, disclosing that it has more than 10 product candidates it’s been developing over the last three years. The therapies are built on the company’s AAV-based platform, Transjoin, which is designed to have patients' livers express bispecific antibodies that bind to both CD3 on T-cells and various targets on tumor cells.
Candid Therapeutics Inc. launched with ex-China control of two bispecific T-cell engager antibodies that it plans to develop for autoimmune diseases. The San Diego-based company will start off with a pocketful of cash, having raised over $370 million for the development of the in-licensed candidates.
Candid Therapeutics Inc. launched with ex-China control of two bispecific T-cell engager antibodies that it plans to develop for autoimmune diseases. The San Diego-based company will start off with a pocketful of cash, having raised over $370 million for the development of the in-licensed candidates.
During a webinar arranged by Demy-Colton, panelists discussed a wide range of potential outcomes that might occur depending on which political party ends up in power next year. From tweaks to the Inflation Reduction Act to new laws to the Federal Trade Commission's regulation of M&As, there’s potential for the government to have substantial effects on the drug development industry.
Diakonos Oncology Corp. has developed a process to manufacture dendritic cell vaccines that the company believes are substantially more potent than its predecessors.
Ideaya Biosciences Inc. appears to be in the lead to develop a treatment for tumors with deletions in both copies of methylthioadenosine phosphorylase (MTAP). Despite the large market with an estimated annual incidence rate in the U.S. of approximately 75,000 patients, there are no FDA approved therapies for MTAP-deleted solid tumors.
